News | April 05, 2009

Baylor Chooses Carestream Molecular Imaging’s Technology for In-Vivo Research

April 6, 2009 — Baylor College of Medicine (BCM) is using optical molecular imaging technology from Carestream Molecular Imaging to advance the study of diseases and therapies involving cancer, cardiovascular disease, infectious agents, inflammatory disease and other conditions.
The company’s KODAK In-Vivo Multispectral Imaging System FX is installed at BCM’s Frensley Center for Imaging Research, which uses imaging to support development of novel agents and other research tools used in the detection and treatment of diseases. Researchers apply the system to a wide variety of imaging techniques that combine optical and X-ray, as well as other modalities such as PET and SPECT isotopes.
“The KODAK Multispectral System combines optical, X-ray and nuclear imaging, allowing us to more precisely localize the molecular signals in vivo — based on the co-registered multi-imaging modalities,” said Shi Ke, M.D., technical director of the Frensley Center for Imaging Research, Baylor College of Medicine. “I believe optical molecular imaging has a bright future, because it will offer more target-specific agents in the light spectrum with accuracy and specificity for disease detection than current PET metabolic agents.
“Optical molecular imaging also delivers the ability to simultaneously test multiple disease markers. Since it usually takes 24 to 48 hours to get results from each test, this will greatly speed disease identification and allow treatment to begin more quickly,” said Dr. Ke.
The Frensley Center for Imaging Research emphasizes the combination of chemistry and biology research. Its mission is to serve the imaging research interests of the basic science and clinical faculty. It also focuses upon industrial collaboration with key device, drug, and imaging partners to bring imaging and therapy advances to the clinic and benefit patients.

For more information: http://mi.carestreamhealth.com

Related Content

PET Tracer Gauges Effectiveness of Promising Alzheimer's Treatment

Longitudinal PET imaging with 18F-AV45. PET imaging shows the average 18F-AV45 uptake per animal group at 8 and 13 months of age. A significant interaction of genotype treatment was observed in the cortex (p = 0.0248), hippocampus (p = 0.0071) and thalamus (p = 0.0084), indicating reduced [18F]-AV45 uptake in BACE1 inhibited transgenic mice. Credit: MICA, University of Antwerp, Belgium.

News | Radiopharmaceuticals and Tracers | December 28, 2017
In the December featured basic science article in The Journal of Nuclear Medicine, Belgian researchers report on the...
Vital Unveils Newest Vitrea Advanced Visualization Release at RSNA 2017
Technology | Advanced Visualization | December 04, 2017
Vital Images unveiled the newest version of Vitrea Advanced Visualization software, the cornerstone of its imaging...
Michael J. Fox Foundation and Tau Consortium Developing PET Tracers for Neurodegenerative Disease
News | Radiopharmaceuticals and Tracers | October 27, 2017
The Michael J. Fox Foundation for Parkinson's Research (MJFF) and the Tau Consortium announced a funding partnership to...
Netherlands Cancer Institute Exploring Molecular Imaging Technology for Prostate Cancer Surgery
News | Molecular Imaging | October 26, 2017
The Netherlands Cancer Institute (NKI) announced it has received funding from the Dutch Cancer Society (KWF...
SNMMI Publishes New FDG PET/CT Appropriate Use Criteria
News | PET-CT | October 25, 2017
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published appropriate use criteria (AUC) for FDG PET/...
Biodex Unveils Atomlab 500 Dose Calibrator and Wipe Test Counter
Technology | Nuclear Imaging | October 19, 2017
Biodex Medical Systems announced the full release of the Atomlab Dose Calibrator and Wipe Test Counter to the market...
ASNC and ASE Team Up to Expand ImageGuide Registry
News | Cardiovascular Ultrasound | October 12, 2017
The American Society of Nuclear Cardiology (ASNC) and the American Society of Echocardiography (ASE) jointly announced...
MR Solutions Showcases Multimodality MRI Solutions on Two Continents
News | Magnetic Resonance Imaging (MRI) | October 11, 2017
October 11, 2017 — MR Solutions took their cryogen-free preclinical multimodality...
Majority of Recurrent Prostate Cancer Patients' Treatment Plan Changed Following Fluciclovine 18F PET/CT
News | Prostate Cancer | October 04, 2017
Blue Earth Diagnostics recently announced the results of a pre-planned interim analysis from an investigational...
News | Business | September 19, 2017
September 19, 2017 — Invicro LLC, a provider of imaging services and software for research and drug development, anno
Overlay Init